Cipla Latest Updates

Management and Leadership Changes Significant leadership transitions took effect on April 1, 2026. Achin Gupta has officially assumed the role of Managing Director and Global CEO for a five-year term, succeeding Umang Vohra. Additionally, Meera Vanjari has taken over as the Global General Counsel. These changes follow the earlier departure of Pradeep Bhadauria, the Global Chief Scientific Officer, who left the company on March 31, 2026. Financial Performance (Q3 FY26) In its most recent quarterly report (Q3 FY26), Cipla reported a 57% year-on-year decline in consolidated net profit, which fell to ₹675.80 crore. While domestic revenue in India grew by 10%, the overall performance was heavily impacted by a 22% decline in North American revenue. This slump was primarily attributed to lower sales of the generic drug Revlimid and a production halt at a key manufacturer for Lanreotide, a major revenue-contributing tumor drug. Regulatory and Manufacturing Updates In February 2026, Cipla's U.S. subsidiary, InvaGen Pharmaceuticals, received two inspection observations (Form 483) from the USFDA following a pre-approval inspection at its facility in Hauppauge, New York. The company is currently working to address these observations to prevent delays in upcoming product approvals for the U.S. market. Product Pipeline and Future StrategyCipla has outlined an ambitious plan to launch seven new products by the end of 2026, focusing on respiratory assets and peptide products. A key upcoming launch includes Gadvair, which is scheduled for the fourth quarter of FY26. To support these launches and long-term growth, the company significantly increased its R&D expenditure by over 37% in the recent quarter.